Moreover, the experimental study of the combination of PI3K inhibition (GDC-0941) with HER2 inhibitors (trastuzumab, pertuzumab) showed that the high efficacy of this combination therapy is a general effect for different breast cancer cell lines despite the fact that different cell lines have different susceptibilities/resistance to each drug separately (42). Here, PIK3CA is linked to breast carcinoma.